Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Matinas BioPharma Holdings Inc MTNB

Healthcare Biotechnology
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged... see more

Bullboard (NYSEAM:MTNB)

View:
User Avatar Image
(9)
•••
  • MikeTesterX
Post by MikeTesteron Aug 02, 2024 10:35am

Matinas BioPharma Holdings, Inc. (MTNB): Unlocking the Poten

https://beyondspx.com/2024/07/31/matinas-biopharma-holdings-inc-mtnb-unlocking-the-potential-of-lipid-nanocrystal-platform-delivery-technology/
30
User Avatar Image
(280)
•••
  • whytestocksX
Post by whytestockson Jun 24, 2024 1:30pm

Matinas BioPharma Reports Successful Treatment of Patient wi

Breaking News: $MTNB Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access ProgramBEDMINSTER, N.J., June ...more  
40
User Avatar Image
(280)
•••
  • whytestocksX
Post by whytestockson Feb 26, 2024 2:45pm

Matinas BioPharma Provides Positive Outcomes Update on the M

BREAKING NEWS: $MTNB Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionA total ...more  
65
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities